GE•benzinga•
GE Healthcare And Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease; Co. Reports The Trial Met Co-Primary Endpoints And First Key Secondary Endpoints
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 13, 2022 by benzinga